I-MOVE multicentre case–control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?

Eurosurveillance

Volumn 21, Issue 16, 2016, Pages

  Kissling, Esther ^a   Nunes, B ^b   Robertson, C ^c,d,e   Valenciano, M ^a   Reuss, A ^f   Larrauri, A ^g,h   Cohen, J M ⁱ   Oroszi, B ^j   Rizzo, C ^k   Machado, A ^b   Pitigoi, D ^l,m   Domegan, L ⁿ   Paradowska Stankiewicz, I ^o   Buchholz, U ^f   Gherasim, A ^g   Daviaud, I ⁱ   Horvath J K ^j   Bella, A ^k   Lupulescu, E ^l   O'Donnell, J ⁿ   Korczynska M ^o   Moren, A ^a   Mosnier, Anne ⁱ   Buda, Silke ^p   Prahm, Kerstin ^p   Schweiger, Brunhilde ^f   Wedde, Marianne ^f   Biere, Barbara ^f   Ferenczi, Annamária ^q   Hercegh, Éva ^r   Giese, Coralie ^n,s   Rogalska, Justyna ^n,s   Rebollado, Javiera ^n,s   Alfonsi, Valeria ^k   Castrucci, Maria Rita ^k   Puzzeli, Simona ^k   Rodrigues, Ana ^b   Guiomar, Raquel ^b   Costa, Inês ^b   Cristóvão, Paula ^b   Lazar, Mihaela ^t   Ivanciuc, Alina Elena ^t   Cherciu, Carmen Maria ^t   Mihai, Maria Elena ^t   Tecu, Cristina ^t   Necula, Gheorge ^t   Jiménez Jorge, Silvia ^g   Castilla, Jesús ^u   Carril, Fernando González ^v   Castrillejo, Daniel ^w   Pozo, Francisco ^x   Altzíbar, Jone ^y   Cenoz, Manuel García ^u   Lozano, José ^z   Martínez Ochoa, Eva ^aa   Vanrell, Juana ^ab   more..

^a EPICONCEPT   (France)

^b NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^c HEALTH PROTECTION SCOTLAND   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^e INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^f ROBERT KOCH INSTITUTE   (Germany)

^g CARLOS III INSTITUTE OF HEALTH   (Spain)

^h CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

ⁱ GROG/Open Rome   (France)

^j Istituto Superiore di Sanità ^*  (Hungary)

^k ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^l NATIONAL INSTITUTE FOR RESEARCH AND DEVELOPMENT IN MICROTECHNOLOGIES   (Romania)

^m CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

ⁿ HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^o NATIONAL MEDICINES INSTITUTE   (Poland)

^p Koch Institut   (Germany)

^q SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^r NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^s EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^t Cantacuzino National Institute of Research   (Hungary)

^u INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^v Servicio de Salud Pública   (Spain)

^w Hospital Comarcal de Melilla   (Spain)

^x INSTITUTO DE SALUD CARLOS III   (Spain)

^y Basque Government   (Spain)

^z Departamento de Salud Pública   (Spain)

^aa Servicio de Epidemiologia y Prevencion Sanitaria   (Spain)

^ab Dirección General de Sanidad y Consumo   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CASE CONTROL STUDY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FLU LIKE SYNDROME; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; SENSITIVITY ANALYSIS; CLINICAL TRIAL; DISEASE OUTBREAKS; EUROPE; FEMALE; INFLUENZA, HUMAN; MALE; PREVALENCE; RISK FACTOR; SEASON; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VACCINATION; VIROLOGY;

CASE-CONTROL STUDIES; DISEASE OUTBREAKS; EUROPE; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PREVALENCE; RISK FACTORS; SEASONS; TREATMENT OUTCOME; VACCINATION;

EID: 85015354198     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2016.21.16.30201     Document Type: Article

References (37)

1. VENICE III Consortium. National seasonal influenza vaccination survey for 2012-13 influenza season in EU/EEA. November 2013-June 2014. Available from: http://venice.cineca.org/ VENICE_Seasonal_Influenza_2012-13_v10.pdf
2. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret A-S, Rizzo C, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One. 2011;6(11):e27622. DOI: 10.1371/journal.pone.0027622 PMID: 22110695
3. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?J Infect Dis. 2008;197(4):490-502. DOI: 10.1086/524146 PMID: 18275271
4. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre casecontrol study. Euro Surveill. 2013;18(5):20390.PMID: 23399425
5. Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratoryconfirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill. 2013;18(5):20389.PMID: 23399424
6. Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M, et al., Primary Health Care Sentinel Network, Network for Influenza Surveillance in Hospitals of Navarre. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12.Euro Surveill. 2013;18(5):20388.PMID: 23399423
7. Jimenez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al., Spanish Influenza Sentinel Surveillance System. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.BMC Infect Dis. 2013;13(1):441. DOI: 10.1186/1471-2334-13-441 PMID: 24053661
8. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season.Vaccine. 2015;33(1):246-51. DOI: 10.1016/j. vaccine.2014.06.052 PMID: 24962752
9. Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus.J Mol Evol. 2008;66(6):655-63. DOI: 10.1007/ s00239-008-9119-z PMID: 18504518
10. Bedford T, Suchard MA, Lemey P, Dudas G, Gregory V, Hay AJ, et al. Integrating influenza antigenic dynamics with molecular evolution. eLife. 2014;3:e01914. DOI: 10.7554/eLife.01914 PMID: 24497547
11. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection.J Infect Dis. 2011;204(12):1879-85. DOI: 10.1093/infdis/jir661 PMID: 21998477
12. Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Vaccines (Basel). 2014;2(4):707-34. DOI: 10.3390/vaccines2040707 PMID: 26344888
13. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014;19(6):20701. DOI: 10.2807/1560-7917.ES2014.19.6.20701 PMID: 24556348
14. Valenciano M, Kissling E, Reuss A, Jimenez-Jorge S, Horvath JK, Donnell JMO, et al., I-MOVE Multicentre Case Control Study Team. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).Vaccine. 2015;33(24):2813-22. DOI: 10.1016/j.vaccine.2015.04.012 PMID: 25936723
15. Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks.Vaccine. 2010;28(46):7381-8. DOI: 10.1016/j.vaccine.2010.09.010 PMID: 20851086
16. Valenciano M, Kissling E, Cohen J-M, Oroszi B, Barret A-S, Rizzo C, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011;8(1):e1000388. DOI: 10.1371/journal.pmed.1000388 PMID: 21379316
17. European Centre for Disease Prevention and Control (ECDC). Protocol for case-control studies to measure influenza vaccine effectiveness in the European Union and European Economic Area Member States. Stockholm: ECDC; 2009. Available from: http://www.ecdc.europa.eu/en/publications/ Publications/0907_TED_Influenza_AH1N1_Measuring_ Influenza_Vaccine_Effectiveness_Protocol_Case_Control_ Studies.pdf
18. European Commission. Commission Decision 2009/363/ EC of 30 April 2009 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. 2009 Jan p. 58. Report No.: OJ L 110. Available from: http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2009:110:0058:0059:EN:P DF
19. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index?Psychol Methods. 2006;11(2):193-206. DOI: 10.1037/1082-989X.11.2.193 PMID: 16784338
20. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001. 568 p.
21. Guess HA. Exposure-time-varying hazard function ratios in case-control studies of drug effects.Pharmacoepidemiol Drug Saf. 2006;15(2):81-92. DOI: 10.1002/pds.1164 PMID: 16287211
22. Nichol K, Nicholson K, Webster RG, Hay AJ. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. Textbook of influenza. Blackwell Science; 1998.
23. Boni MF, Gog JR, Andreasen V, Feldman MW. Epidemic dynamics and antigenic evolution in a single season of influenza A.Proc Biol Sci. 2006;273(1592):1307-16. DOI: 10.1098/rspb.2006.3466 PMID: 16777717
24. Hobson D. The potential role of immunological adjuvants in influenza vaccines.Postgrad Med J. 1973;49(569):180-4. DOI: 10.1136/pgmj.49.569.180 PMID: 4802631
25. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates.J Infect Dis. 1996;174(6):1168-75. DOI: 10.1093/infdis/174.6.1168 PMID: 8940205
26. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach.Expert Rev Vaccines. 2012;11(8):985-94. DOI: 10.1586/erv.12.61 PMID: 23002979
27. Foy HM, Cooney MK, McMahan R. A Hong Kong influenza immunity three years after immunization.JAMA. 1973;226(7):758-61. DOI: 10.1001/jama.1973.03230070024006 PMID: 4800628
28. World Health Organisation (WHO). WHO recommendations on the composition of influenza virus vaccines [Accessed on 22 Oct 2015]. Available from: http://www.who.int/influenza/ vaccines/virus/recommendations/en/
29. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horvath JK, et al.,. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill. 2016;21(7):30139.
30. European Centre for Disease Prevention and Control (ECDC). Influenza Surveillance in Europe; Season 2011-12. Stockholm: ECDC; 2012.Available from: http://ecdc.europa.eu/en/ publications/Publications/Influenza-Europe-2011-2012-surveillance-report.pdf
31. European Centre for Disease Prevention and Control (ECDC). Influenza in Europe-season 2013-14. Stockholm: ECDC; 2014. Available from: http://ecdc.europa.eu/en/publications/ Publications/Influenza-2013-14-season-report.pdf
32. European Centre for Disease Prevention and Control (ECDC). Risk Assessment-Seasonal influenza in the EU/EEA countries 2014/15. Stockholm, ECDC; 2015. Available from: http://ecdc. europa.eu/en/publications/Publications/seasonal-influenzarisk-assessment.pdf
33. Sullivan SG, Komadina N, Grant K, Jelley L, Papadakis G, Kelly H. Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match.J Med Virol. 2014;86(6):1017-25. DOI: 10.1002/jmv.23847 PMID: 24395730
34. Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility.J Infect Dis. 2015;211(10):1519-28. DOI: 10.1093/infdis/jiu650 PMID: 25416812
35. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4):21022. DOI: 10.2807/1560-7917. ES2015.20.4.21022 PMID: 25655053
36. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59(10):1375-85. DOI: 10.1093/cid/ ciu680 PMID: 25270645
37. Consejo interterritorial, Sistema Nacional de Salud. Recomendaciones de vacunacion frente a la gripe, Temporada 2015-2016. 9 Sep 2015 [Accessed on 24 Nov 2015]. Available from: http://www.msssi.gob.es/profesionales/saludPublica/ prevPromocion/vacunaciones/docs/Recomendaciones_ vacunacion_gripe2015_2016.pdf